Marion M Mafham1, Natalie Staplin1, Jonathan Emberson1, Richard Haynes1, William Herrington1, Christina Reith1, Christoph Wanner2, Robert Walker3, Alan Cass4, Adeera Levin5, Bengt Fellström6, Lixin Jiang7, Hallvard Holdaas8, Bertram Kasiske9, David C Wheeler10, Martin J Landray1, Colin Baigent1. 1. Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, Oxford, UK. 2. Department of Medicine 1, Division of Nephrology, University of Wuerzburg, Wuerzburg, Germany. 3. Dunedin School of Medicine, University of Otago, Otago, New Zealand. 4. Menzies School of Health Research, Charles Darwin University, Darwin, Australia. 5. University of British Columbia, Vancouver, British Columbia, Canada. 6. University Hospital, Uppsala, Sweden. 7. National Clinical Research Centre of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. 8. Renal Section, Department of Transplant Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway. 9. Hennepin County Medical Centre and the University of Minnesota, Minneapolis, MN, USA. 10. University College London, London, UK.
Abstract
Background: Estimated albumin excretion rate (eAER) provides a better estimate of 24-h albuminuria than albumin:creatinine ratio (ACR). However, whether eAER is superior to ACR in predicting end-stage renal disease (ESRD), vascular events (VEs) or death is uncertain. Methods: The prognostic utility of ACR and eAER (estimated from ACR, sex, age and race) to predict mortality, ESRD and VEs was compared using Cox proportional hazards regression among 5552 participants with chronic kidney disease in the Study of Heart and Renal Protection, who were not on dialysis at baseline. Results: During a median follow-up of 4.8 years, 1959 participants developed ESRD, 1204 had a VE and 1130 died (641 from a non-vascular, 369 from a vascular and 120 from an unknown cause). After adjustment for age, sex and eGFR, both ACR and eAER were strongly and similarly associated with ESRD risk. The average relative risk (RR) per 10-fold higher level was 2.70 (95% confidence interval 2.45-2.98) for ACR and 2.67 (2.43-2.94) for eAER. Neither ACR nor eAER provided any additional prognostic information for ESRD risk over and above the other. For VEs, there were modest positive associations between both ACR and eAER and risk [adjusted RR per 10-fold higher level 1.37 (1.22-1.53) for ACR and 1.36 (1.22-1.52) for eAER]. Again, neither measure added prognostic information over and above the other. Similar results were observed when ACR and eAER were related to vascular mortality [RR per 10-fold higher level: 1.64 (1.33-2.03) and 1.62 (1.32-2.00), respectively] or to non-vascular mortality [1.53 (1.31-1.79) and 1.50 (1.29-1.76), respectively]. Conclusions: In this study, eAER did not improve risk prediction of ESRD, VEs or mortality.
RCT Entities:
Background: Estimated albumin excretion rate (eAER) provides a better estimate of 24-h albuminuria than albumin:creatinine ratio (ACR). However, whether eAER is superior to ACR in predicting end-stage renal disease (ESRD), vascular events (VEs) or death is uncertain. Methods: The prognostic utility of ACR and eAER (estimated from ACR, sex, age and race) to predict mortality, ESRD and VEs was compared using Cox proportional hazards regression among 5552 participants with chronic kidney disease in the Study of Heart and Renal Protection, who were not on dialysis at baseline. Results: During a median follow-up of 4.8 years, 1959 participants developed ESRD, 1204 had a VE and 1130 died (641 from a non-vascular, 369 from a vascular and 120 from an unknown cause). After adjustment for age, sex and eGFR, both ACR and eAER were strongly and similarly associated with ESRD risk. The average relative risk (RR) per 10-fold higher level was 2.70 (95% confidence interval 2.45-2.98) for ACR and 2.67 (2.43-2.94) for eAER. Neither ACR nor eAER provided any additional prognostic information for ESRD risk over and above the other. For VEs, there were modest positive associations between both ACR and eAER and risk [adjusted RR per 10-fold higher level 1.37 (1.22-1.53) for ACR and 1.36 (1.22-1.52) for eAER]. Again, neither measure added prognostic information over and above the other. Similar results were observed when ACR and eAER were related to vascular mortality [RR per 10-fold higher level: 1.64 (1.33-2.03) and 1.62 (1.32-2.00), respectively] or to non-vascular mortality [1.53 (1.31-1.79) and 1.50 (1.29-1.76), respectively]. Conclusions: In this study, eAER did not improve risk prediction of ESRD, VEs or mortality.
Authors: Ron T Gansevoort; Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh Journal: Kidney Int Date: 2011-02-02 Impact factor: 10.612
Authors: Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Ron T Gansevoort Journal: Lancet Date: 2010-05-17 Impact factor: 79.321
Authors: Chetana N Naresh; Andrew Hayen; Alexander Weening; Jonathan C Craig; Steven J Chadban Journal: Am J Kidney Dis Date: 2013-08-16 Impact factor: 8.860
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Richard Haynes; Natalie Staplin; Jonathan Emberson; William G Herrington; Charles Tomson; Lawrence Agodoa; Vladimir Tesar; Adeera Levin; David Lewis; Christina Reith; Colin Baigent; Martin J Landray Journal: Am J Kidney Dis Date: 2014-03-05 Impact factor: 8.860
Authors: James Fotheringham; Michael J Campbell; Damian G Fogarty; Meguid El Nahas; Timothy Ellam Journal: Am J Kidney Dis Date: 2013-09-29 Impact factor: 8.860
Authors: Pengfei Zhu; William G Herrington; Richard Haynes; Jonathan Emberson; Martin J Landray; Cathie L M Sudlow; Mark Woodward; Colin Baigent; Sarah Lewington; Natalie Staplin Journal: J Am Soc Nephrol Date: 2020-10-30 Impact factor: 10.121
Authors: William G Herrington; Natalie Staplin; Pengfei Zhu; Sarah Lewington; Richard Haynes; Jonathan Emberson; Martin J Landray; David Cherney; Mark Woodward; Colin Baigent Journal: Int J Obes (Lond) Date: 2020-07-16 Impact factor: 5.095